Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein-producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.

被引：0
|
作者：
Wang, Yakun
Wang, Chang
Chen, Xiaofeng
Peng, Zhi
Gu, Yanhong
Wang, Yizhuo
Wang, Xicheng
Li, Jian
Gong, Jifang
Qi, Changsong
Yuan, Jiajia
Lu, Zhihao
Lu, Ming
Shen, Lin
Cao, Yanshuo
Zhang, Xiaotian
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
[2] First Hosp Jilin Univ, Canc Ctr, Changchun, Jilin, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Oncol Dept, Nanjing, Jiangsu, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Early Drug Dev Ctr, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Early Drug Dev Ctr, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
613-135-244-3829; 283-9769-3573-426; 261-492-3532-2370-7650-2700; 3282-270-434-6184; 261-492-3532-2370-5109; 261-492-2769; 261-566-11347; 4; 3; 2; 3599; 239; 2950; 2425; 5; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.351
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 351
页数：1
相关论文
共 50 条
  • [31] First-line panitumumab plus docetaxel and cisplatin in advanced gastric or gastroesophageal junction adenocarcinoma: Results of a phase II trial (SPIGA).
    Aldana, Guillermo Alfonso Quintero
    Folgar, Sonia Candamio
    Mendez, Jose Carlos Mendez
    Reboredo, Margarita
    Fernandez, Monica Jorge
    Constenla, Manuel
    Reinoso, Carlos Romero
    Fernandez, Mercedes Salgado
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
    Li, Ning
    Deng, Wen-Ying
    Ma, Yi-Jie
    Bie, Liang-Yu
    Zhang, Chi
    Wei, Chen
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 367 - 367
  • [33] Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial
    He, Minke
    Du, Zefeng
    Lai, Zhicheng
    Kan, Anna
    Shi, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
    Zhaoqing Tang
    Yan Wang
    Yiyi Yu
    Yuehong Cui
    Liang Liang
    Chen Xu
    Zhenbin Shen
    Kuntang Shen
    Xuefei Wang
    Tianshu Liu
    Yihong Sun
    BMC Medicine, 20
  • [35] Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
    Tang, Zhaoqing
    Wang, Yan
    Yu, Yiyi
    Cui, Yuehong
    Liang, Liang
    Xu, Chen
    Shen, Zhenbin
    Shen, Kuntang
    Wang, Xuefei
    Liu, Tianshu
    Sun, Yihong
    BMC MEDICINE, 2022, 20 (01)
  • [36] Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
    Li Yuan
    Guo-Dong Jia
    Xiao-Fei Lv
    Si-Yi Xie
    Shan-Shan Guo
    Da-Feng Lin
    Li-Ting Liu
    Dong-Hua Luo
    Yi-Fu Li
    Shen-Wen Deng
    Ling Guo
    Mu-Sheng Zeng
    Xiu-Yu Cai
    Sai-Lan Liu
    Xue-Song Sun
    Xiao-Yun Li
    Su-Chen Li
    Qiu-Yan Chen
    Lin-Quan Tang
    Hai-Qiang Mai
    Nature Communications, 14
  • [37] Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
    Yuan, Li
    Jia, Guo-Dong
    Lv, Xiao-Fei
    Xie, Si-Yi
    Guo, Shan-Shan
    Lin, Da-Feng
    Liu, Li-Ting
    Luo, Dong-Hua
    Li, Yi-Fu
    Deng, Shen-Wen
    Guo, Ling
    Zeng, Mu-Sheng
    Cai, Xiu-Yu
    Liu, Sai-Lan
    Sun, Xue-Song
    Li, Xiao-Yun
    Li, Su-Chen
    Chen, Qiu-Yan
    Tang, Lin-Quan
    Mai, Hai-Qiang
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [38] Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
    Wei, Jia
    Lu, Xiaofeng
    Liu, Qin
    Fu, Yao
    Liu, Song
    Zhao, Yang
    Zhou, Jiawei
    Chen, Hui
    Wang, Meng
    Li, Lin
    Yang, Ju
    Liu, Fangcen
    Zheng, Liming
    Yin, Haitao
    Yang, Yang
    Zhou, Chong
    Zeng, Ping
    Zhou, Xiaoyu
    Ding, Naiqing
    Chen, Shiqing
    Zhao, Xiaochen
    Yan, Jing
    Fan, Xiangshan
    Guan, Wenxian
    Liu, Baorui
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [39] Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
    Jia Wei
    Xiaofeng Lu
    Qin Liu
    Yao Fu
    Song Liu
    Yang Zhao
    Jiawei Zhou
    Hui Chen
    Meng Wang
    Lin Li
    Ju Yang
    Fangcen Liu
    Liming Zheng
    Haitao Yin
    Yang Yang
    Chong Zhou
    Ping Zeng
    Xiaoyu Zhou
    Naiqing Ding
    Shiqing Chen
    Xiaochen Zhao
    Jing Yan
    Xiangshan Fan
    Wenxian Guan
    Baorui Liu
    Nature Communications, 14
  • [40] Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial
    Cheng, Xiangdong
    Xu, Zhiyuan
    Hu, Can
    Zhang, Yanqiang
    Pengfei, Yu
    Du, Yian
    Yang, Litao
    Zhang, Ruolan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345